SOURCE: GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - Jul 2, 2012) - GlobeImmune, Inc., today announced that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. GlobeImmune previously submitted its registration statement to the SEC on a confidential basis under the Jumpstart Our Business Startups Act. The number of shares to be offered and the price range for the offering have not been determined. The Company has filed an application for its common stock to be listed on the NASDAQ Global Market under the symbol "GBIM."
Wells Fargo Securities, LLC, and Piper Jaffray & Co. will act as joint book-running managers for the offering. JMP Securities, LLC, will act as co-manager.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from:
Wells Fargo Securities, LLC
Attention: Equity Syndicate Department
375 Park Avenue
New York, New York 10152
Toll-free: (800) 326-5897
Piper Jaffray & Co.
Attention: 800 Nicollet Mall, J12S03
Minneapolis, MN 55402
Toll-free: (800) 747-3924
GlobeImmune is a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on its proprietary Tarmogen platform. Tarmogens activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines, which stimulate predominately antibody production. To date, Tarmogen product candidates have been generally well tolerated in clinical trials for multiple disease indications and are efficient to manufacture. In May 2009, the company entered into a collaboration agreement with Celgene Corporation focused on the discovery, development and commercialization of product candidates for the treatment of cancer. In October 2011, the company entered into a worldwide, strategic collaboration with Gilead Sciences, Inc., to develop Tarmogens for the treatment of chronic hepatitis B infection. For additional information, please visit the company's website at www.globeimmune.com.